Literature DB >> 14523629

Specific modulation of sigma binding sites by the anxiolytic drug opipramol.

G Holoubek1, W E Müller.   

Abstract

The atypical anxiolytic and antidepressive drug opipramol binds with high affinity to sigma1 and somewhat lower affinity to sigma2 sites. After subchronic treatment, opipramol significantly down-regulated sigma2 but not sigma1 sites. This effect was not seen for imipramine, citalopram, and reboxetine under similar conditions. On the other hand, only imipramine reduced the number of sigma1 sites. It is suggested that effects at sigma2 sites are involved in the anxiolytic properties of opipramol.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523629     DOI: 10.1007/s00702-003-0019-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  5 in total

Review 1.  Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Shang-Yi Tsai; Tomohisa Mori; Michiko Fujimoto; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2011-03-05       Impact factor: 6.902

2.  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Authors:  Melanie A Paquette; Katherine Foley; Elizabeth G Brudney; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Psychopharmacology (Berl)       Date:  2009-03-13       Impact factor: 4.530

3.  Consecutive Controlled Case Series on Effectiveness of Opipramol in Severe Sleep Bruxism Management-Preliminary Study on New Therapeutic Path.

Authors:  Mieszko Wieckiewicz; Helena Martynowicz; Tomasz Wieczorek; Anna Wojakowska; Katarzyna Sluzalec-Wieckiewicz; Pawel Gac; Rafal Poreba; Grzegorz Mazur; Efraim Winocur; Joanna Smardz
Journal:  Brain Sci       Date:  2021-01-22

4.  Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole.

Authors:  Mikhail V Voronin; Yulia V Vakhitova; Inna P Tsypysheva; Dmitry O Tsypyshev; Inna V Rybina; Rustam D Kurbanov; Elena V Abramova; Sergei B Seredenin
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

5.  Introduction of sustained release opipramol dihydrochloride matrix tablets as a new approach in the treatment of depressive disorders.

Authors:  Umit Gönüllü; Melike Uner; Gülgün Yener; Turan Altınkurt
Journal:  Int J Biomed Sci       Date:  2006-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.